This comprehensive update on the management of encapsulating peritoneal sclerosis incorporates insights gained from recently published findings and the accumulated experience of the authors. Aspects covered include diagnosis, risk factors and predictive markers, treatment, and prevention, including criteria for withdrawal from peritoneal dialysis.
KawaguchiY., IshizukaT., ImadaA., OohiraS., KuriyamaS., NakamotoH.Searching for the reasons for drop-out from peritoneal dialysis: A nationwide survey in Japan.Perit Dial Int2003; 23(Suppl 2): S175–7.
2.
Imada A, Kawaguchi Y, Kumano K, Nomoto Y, for the CAPD-Related Peritonitis Study Group in Japan.A multicenter study of CAPD-related peritonitis in Japan (Japanese).J Jpn Soc Dial Ther2001; 34: 1157–62.
3.
NakaiS., ShinzatoT., NaguraY., MasakaneI., KitaokaT., ShinodaT. for the Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001).Ther Apher Dial2004; 8: 3–32.
4.
NomotoY., KawaguchiY., KuboH., HiranoH., SakaiS., KurokawaK.Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.Am J Kidney Dis1996; 28: 420–7.
5.
Kawanishi H, for the Long-Term Peritoneal Dialysis Study Group.Encapsulating peritoneal sclerosis in Japan: Prospective multicenter controlled study.Perit Dial Int2001; 21(Suppl 3): S67–71.
6.
NakamotoH., KawaguchiY., SuzukiH.Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan.Adv Perit Dial2002; 18: 119–23.
7.
KawanishiH., KawaguchiY.Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS)—a multicenter study in Japan (Japanese).Jin To Toseki2000; 49(Suppl): 225–8.
8.
RigbyR.J., HawleyC.M.Sclerosing peritonitis: The experience in Australia.Nephrol Dial Transplant1998; 13: 154–9.
9.
OulesR., ChallahS., BrunnerF.P.Case-control study to determine the cause of sclerosing peritoneal disease.Nephrol Dial Transplant1988; 3: 66–9.
10.
RottembourgJ., IssadB., LangloisP., TranbalocR., AdamouA., DeGrocF.Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD: Evaluation of the potential risk factors.Adv CAPD1985; 1: 109–17.
CelicoutB., LevardH., HayJ., MsikaS., FingerhutA., PelissierE.Sclerosing encapsulating peritonitis: Early and late results of surgical management in 32 cases. French Associations for Surgical Research.Dig Surg1998; 15: 697–702.
13.
KawaguchiY., KawanishiH., MujaisS., TopleyN., OreopoulosD.G.Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.Perit Dial Int2000; 20(Suppl 4): S43–55.
14.
NomotoY., KawaguchiY., SakaiS., HiranoH., KuboH., OhiraS.Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis—definition, diagnosis, and treatment recommendations, 1997 update (Japanese).J Jpn Soc Dial Ther1998; 31: 303–11.
15.
KawanishiH., HaradaY., NoriyukiT., KawaiT., TakahashiS., MoriishiM.Treatment options for encapsulating peritoneal sclerosis based on progressive stage.Adv Perit Dial2001; 17: 200–4.
16.
MactierR.A.The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis.Adv Perit Dial2000; 16: 223–8.
17.
TaylorP.M.Image-guided peritoneal access and management of complications in peritoneal dialysis.Semin Dial2002; 15: 250–8.
18.
CampbellS., ClarkeP., HawleyC., WiganM., KerlinP., ButlerJ.Sclerosing peritonitis: Identification of diagnostic, clinical, and radiological features.Am J Kidney Dis1994; 24: 819–25.
19.
HollmanA.S., McMillanM.A., BriggsJ.D., JunorB.J., MorleyP.Ultrasound changes in sclerosing peritonitis following continuous ambulatory peritoneal dialysis.Clin Radiol1991; 43: 176–9.
20.
VerbanckJ.J., SchoonjansR.S., VandewieleI.A., SegaertM.F., CrollaD.P., TangheW.R.Sclerosing peritonitis with gross peritoneal calcification and abdominal wall abscess secondary to bowel perforation: Ultrasonographic appearance.J Clin Ultrasound1997; 25: 136–40.
21.
HareC.M.Radiological view of sclerosing peritonitis.Nephrol Dial Transplant1999; 14: 497–8.
KorzetsA., KorzetsZ., PeerG., PapoJ., SternD., BernheimJ.Sclerosing peritonitis. Possible early diagnosis by computerized tomography of the abdomen.Am J Nephrol1988; 8: 143–6.
24.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R., for the Peritoneal Biopsy Study Group. Morphological changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
25.
OhsukiH., OgawaH., OnoM., SaitoA.Ultrasonographic evaluation of mesentery in CAPD patients. In: OtaK., MaherJ., WinchesterJ., HirszelP., eds. Current Concepts in Peritoneal Dialysis.Amsterdam: Excerpta Medica; 1992: 489–93.
26.
YamamotoT., IzumotaniT., OtoshiT., KimM.Morphological studies of mesothelial cells in CAPD effluent and their clinical significance.Am J Kidney Dis1998; 32: 946–52.
27.
NakayamaM., YamamotoH., IkedaM., HasegawaT., KatoN., TakahashiH.Risk factors and preventive measures for encapsulating peritoneal sclerosis—Jikei experience 2002.Adv Perit Dial2002; 18: 144–8.
28.
KawanishiH., KawaguchiY.Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS)—a multicenter study in Japan (Japanese).Jin To Toseki2000; 49(Suppl): 225–8.
29.
NakayamaM., IkedaM., KatohN., HayakawaH., NumataM., OtsukaY.Long-standing high-transport membrane as a risk factor for EPS development after PD withdrawal: An analysis based on changes in peritoneal function during and after CAPD withdrawal (Japanese).Nippon Jinzo Gakkai Shi2002; 44: 396–401.
30.
MoriishiM., KawanishiH., KawaiT., TakahashiS., HiraiT., ShishidaM.Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.Adv Perit Dial2002; 18: 149–53.
31.
KeatingJ.P., NeillM., HillG.L.Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine.Aust N Z J Surg1997; 67: 742–4.
32.
MackowR.C., ArgyW.P., WinchesterJ.F., RakowskiT.A., FieldsP.A., RotellarC.Sclerosing encapsulating peritoneal in rat induced by long-term intraperitoneal administration of antiseptics.J Lab Clin Med1998; 112: 363–71.
33.
MackowR.C., WinchesterJ.F., ArgyW.P., AndrewP.M., FieldsP.A., BatesS.Sclerosing encapsulating peritoneal in rats: An experimental study with intraperitoneal antiseptics.Contrib Nephrol1987; 57: 213–18.
34.
LoW.K., ChanK.T., LeungA.C., PangS.W., TseC.Y.Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol.Adv Perit Dial1990; 6: 79–84.
35.
Wieczorowska–TobisK., PolubinskaA., BreborowiczA., OreopoulosD.A comparison of the biocompatibility of phosphate-buffered saline and Dianeal 3.86% in the rat model of peritoneal dialysis.Adv Perit Dial2001; 17: 42–6.
36.
DasguptaM.Strategies for intervention in and prevention of biofilm-related infection in peritoneal dialysis patients.Adv Perit Dial2003; 19: 195–7.
37.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
38.
YamamotoR., NakayamaM., HasegawaT., MiwakoN., YamamotoH., YokoyamiK.High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.Adv Perit Dial2002; 18: 131–4.
HeimbürgerO., WaniewskiJ., WerynskiA., TranæusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss ultrafiltration capacity.Kidney Int1990; 38: 495–506.
42.
KredietR.T.Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.Perit Dial Int2001; 21: 560–7.
43.
WangT., ChenC., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis.J Am Soc Nephrol1997; 8: 1915–20.
44.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.Growth factors VEGF and TGF-β1 in peritoneal dialysis.J Lab Clin Med1999; 134: 124–32.
45.
SzetoC.C., WongT.Y., LaiK.B., ChowK.M., LiP.K.The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis.Perit Dial Int2002; 22: 265–74.
Pecoits–FilhoR., AraujoM.R., LindholmB., StenvinkelP., AbensurH., RomaoJ.E.Jr.. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate.Nephrol Dial Transplant2002; 17: 1480–6.
48.
ZemelD., ImholzA.L., de WaartD.R., DinklaC., StruijkD.G., KredietR.T.Appearance of tumor necrosis factor–α and soluble TNF-receptors I and II in peritoneal effluent of CAPD.Kidney Int1994; 46: 1422–30.
49.
ParkM.S., LeeH.A., ChuW.S., YangD.H., HwangS.D.Peritoneal accumulation of AGE and peritoneal membrane permeability.Perit Dial Int2000; 20: 452–60.
50.
LeeE.A., OhJ.H., LeeH.A., KimS.I., ParkE.W., ParkK.B.Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: Role of aminoguanidine.Perit Dial Int2001; 21: 245–53.
51.
NumataM., NakayamaM., NorforsL., HoffC.M., HolmesC.J., HosoyaT.A single nucleotide polymorphism (SNP) in the RAGE-429 T/C genotype may be related to encapsulated peritoneal sclerosis (EPS) in Japanese peritoneal dialysis (PD) patients (Abstract).J Am Soc Nephrol2003; 14: 214A.
52.
WongT.Y., SzetoC.C., SzetoC.Y., LaiK.B., ChowK.M., LiP.K.Association of eNOS polymorphism with basal peritoneal membrane function in uremic patients.Am J Kidney Dis2003; 42: 781–6.
53.
LeeH.Y., KimB.S., ChoiH.Y., ParkH.C., KangS.W., ChoiK.H.Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea.Nephrology (Carlton)2003; 8(Suppl 2): S33–9.
54.
PollockC.A.Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis.Semin Dial2003; 16: 406–10.
55.
JenkinsS.B., LengB.L., ShortlandJ.R., BrownP.W., WilkieM.E.Sclerosing encapsulating peritonitis: A case series from a single U.K. center during a 10-year period.Adv Perit Dial2001; 17: 191–5.
56.
HendriksP.M., Ho-dac-PannekeetM.M., van GulikT.M., StruijkD.G., PhoaS.S., SieL.Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics.Perit Dial Int1997; 17: 136–43.
PollockC.A.Diagnosis and management of encapsulating peritoneal sclerosis.Perit Dial Int2001; 21(Suppl 3): S61–6.
59.
ImaiH., NakamotoH., FukushimaR., YamanouchiY., IshidaY., SuzukiH.Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis.Adv Perit Dial2002; 18: 124–30.
60.
KawanishiH., KawaguchiY., FukuiH., HaraS., ImadaA., KuboH.Encapsulating peritoneal sclerosis in Japan: A prospective, controlled, multicenter study.Am J Kidney Dis2004; 44: 729–37.
61.
NakamotoH., ImaiH., IshidaY., YamanouchiY., InoueT., OkadaH.New animal models for encapsulating peritoneal sclerosis—role of acidic solution.Perit Dial Int2001; 21(Suppl 3): S349–53.
MoriY., MatsuoS., SutohH., ToriyamaT., KawaharaH., HottaN.A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone.Am J Kidney Dis1997; 30: 275–8.
64.
JunorB.J., McMillanM.A.Immunosuppression in sclerosing peritonitis.Adv Perit Dial1993; 9: 187–9.
65.
EvrenkayaT.R., AtasoyuE.M., UnverS., BasekimC., BalogluH., TulbekM.Y.Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant2004; 19: 2423–4.
66.
del PesoG., BajoM.A., GilF., AguileraA., RosS., CosteroO.Clinical experience with tamoxifen in peritoneal fibrosing syndromes.Adv Perit Dial2003; 19: 32–5.
67.
AllariaP.M., GiangrandeA., GandiniE., PisoniI.B.Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: Tamoxifen as a new therapeutic agent?J Nephrol1999; 12: 395–7.
68.
HoffC.M., ShockleyT.R.Peritoneal dialysis in the 21st century: The potential of gene therapy.J Am Soc Nephrol2002; 13(Suppl 1): S117–24.
69.
MargettsP.J., GyorffyS., KolbM., YuL., HoffC.M., HolmesC.J.Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats.J Am Soc Nephrol2002; 13: 721–8.
70.
OreopoulosD.G., TzamaloukasA.H.Peritoneal dialysis in the next millennium.Adv Ren Replace Ther2000; 7: 338–46.
71.
OtaK., AkibaT., NakaoT., NakayamaM., MaebaT., ParkM.S.Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients.Perit Dial Int2003; 23: 356–61.
72.
DaviesS.J., WoodrowG., DonovanK., PlumJ., WilliamsP., JohanssonA.C.Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial.J Am Soc Nephrol2003; 14: 2338–44.
73.
CookerL.A., ChooC.G., LuneburgP., LamelaJ., HolmesC.J.Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro.Adv Perit Dial1999; 15: 17–20.
74.
BarréD.E., ChenC., CookerL., MoberlyJ.B.Decreased in vitro formation of AGEs with Extraneal solution compared to dextrose-containing peritoneal dialysis solutions.Adv Perit Dial1999; 15: 12–16.
75.
LeeJ.H., ReddyD.K., SaranR., MooreH.L., TwardowskiZ.J., NolphK.D.A.Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.Perit Dial Int2000; 20: 643–51.
76.
BajoM.A., SelgasR., CastroM.A., del PesoG., DiazC., Sanchez–TomeroJ.A.Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo.Perit Dial Int2000; 20: 742–7.
77.
DaviesS., BrownE., RutherfordP., MeeusF., BorrasM., RiegelW.Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription.Kidney Int (In press).
78.
HoffC.M.In vitro biocompatibility performance of Physioneal.Kidney Int2003; 64(Suppl 88): S57–74.
79.
ter WeeP.M., BeelenR.H., van den BornJ.The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions.Kidney Int2003; 64(Suppl 88): S75–83.
YamamotoH., NakayamaM., YamamotoR., OtsukaY., TakahashiH., NatoN.Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: A single-center experience in Japan.Adv Perit Dial2002; 18: 135–8.
